By Fineline Cube China’s National Medical Products Administration (NMPA) announced that the Center for Medical Device Evaluation and the Center for Drug Evaluation have jointly issued the “Notice on Matters Concerning the Simultaneous Development of Anti-Tumor Drugs and Their Companion Diagnostics (Draft for Comments)” on July 31, 2026.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) – CDE & CMDE |
| Document Type | Draft guidance for public comment |
| Focus Area | Anti-tumor drugs and companion diagnostics (CDx) |
| Publication Date | 31 Jul 2026 |
| Key Objective | Improve review efficiency, accelerate clinical availability, standardize CDx application |
| Implementation Status | Open for public comment |
Key Provisions & Requirements
- Parallel Development: If anti-tumor drug requires CDx for patient screening, CDx development should proceed in parallel with drug development
- Joint Clinical Trials: Clinical trials for drug and CDx should be performed jointly when biomarker testing is required
- Registration Timing: Original CDx should be submitted for registration concurrently with drug application
- Post-Marketing Commitment: If CDx not submitted concurrently, drug approval will include CDx development as post-marketing commitment
- Multiplex Assays: For CDx testing multiple biomarkers, separate evaluation evidence required for each biomarker
- Priority Review: CDx co-developed with priority-review anti-tumor drugs may qualify for priority review during registration
Strategic Significance
The draft guidance represents a significant step toward aligning China’s regulatory framework with international standards for precision oncology. By establishing clear requirements for synchronized development, the NMPA aims to:
- Accelerate patient access to innovative targeted therapies
- Ensure diagnostic accuracy and reliability in clinical practice
- Reduce development timelines through coordinated regulatory pathways
- Enhance China’s position as a global leader in precision medicine
Industry Implications
| Stakeholder | Impact |
|---|---|
| Pharmaceutical Companies | Need to integrate CDx development planning early in drug development process |
| Diagnostic Developers | Increased demand for companion diagnostic platforms aligned with oncology pipelines |
| Clinical Trial Sites | Requirement to implement standardized biomarker testing protocols |
| Patients | Improved access to targeted therapies with validated diagnostic selection criteria |
The synchronized development model is expected to particularly benefit emerging modalities such as antibody-drug conjugates and cell therapies, where precise patient selection through companion diagnostics is critical for demonstrating clinical efficacy and safety.
Market Context
China’s oncology market, valued at over $30 billion annually, represents one of the fastest-growing segments in global pharmaceuticals. The new framework could catalyze partnerships between pharmaceutical companies and diagnostic developers, creating new business opportunities while potentially reducing development costs through optimized clinical pathways.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory developments and industry implications. Actual outcomes may differ due to policy changes, implementation challenges, and market dynamics.-Fineline Info & Tech